Legal wrangle gives boost to UK stem-cell research

The future of human stem-cell research – an area with potentially massive implications for the biotech and pharmaceutical industries – could be decided in an American courthouse. The outcome could produce a huge boost for UK-based research.

The future of human stem-cell research – an area with potentially massive implications for the biotech and pharmaceutical industries – could be decided in an American courthouse. The outcome could produce a huge boost for UK-based research.

Since the isolation of human embryonic stem cells by a Wisconsin researcher in 1998, the scientific community has been straining at the leash to embark on research using them. Stem cells are genetic "blank slates" that scientists believe can be made to grow into particular cells in the body. The hope is that the research could be turned into organs for transplant or used to fight disease.

The area has raised high-profile ethical issues, but the suggestion that stem cell research may yield so-called "miracle cures" is gradually gaining strength. President George Bush has now agreed to limited federal funding for human stem-cell research.

But like many other areas of the biotech and pharmaceutical industries, researchers cannot get properly under way until a series of nagging legal issues are ironed out. Just as genes have been patented, so stem cells have prompted a "land grab" for intellectual property rights. Now that has ended in court, and the case will probably be the key to what research will be done and who will end up making the money out of it.

The case has been brought against Geron, the US biotech research firm, and is expected to unleash a lengthy battle over who will dominate the field. "Given that the science has the potential to revolutionise medicine," said one City analyst, "this is going to turn into a very significant battleground."

After the 1998 discovery, Geron paid the University of Wisconsin for its research and received extensive commercial rights to develop the university's five embryonic stem-cell lines. Wisconsin is now suing Geron over the exact ownership of the patents. The problem the court has to work out is just how far Geron's rights extend. If the court finds in its favour, it will virtually guarantee Geron's dominant position in regenerative medicine – the chief area that stem-cell research is targeting.

But the issue immediately brings in other companies working in the field, each eager to protect its interests. One example is BresaGen, an Australian company working on four of its own human embryonic stem-cell lines which recently opened a lab in the US. Already the possibility has been raised of a conflict of intellectual properties, and still more legal wrangling seems to be on the cards.

These may be only the first salvoes, but analysts are convinced that the stakes will get higher. One major beneficiary of all that could be the UK. In this country, where the rights to use embryonic stem cells are less limited than in the US, researchers have staked out a variety of patches.

The industry believes it is therefore likely, given the considerable strength of research in this country, that Britain will become the hub for the new science as it advances.

Start your day with The Independent, sign up for daily news emails
Arts and Entertainment
Attenborough with the primates
tvWhy BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter
News
Campbell: ‘Sometimes you have to be economical with the truth’
newsFormer spin doctor says MPs should study tactics of leading sports figures like José Mourinho
Sport
football
Life and Style
Agretti is often compared to its relative, samphire, though is closer in taste to spinach
food + drink
ebooks
ebooksA special investigation by Andy McSmith
News
Kelly Osbourne will play a flight attendant in Sharknado 2
people
News
Down-to-earth: Winstone isn't one for considering his 'legacy'
people
News
The dress can be seen in different colours
i100
Sport
Wes Brown is sent-off
football
Voices
Lance Corporal Joshua Leakey VC
voicesBeware of imitations, but the words of the soldier awarded the Victoria Cross were the real thing, says DJ Taylor
Life and Style
Alexander McQueen's AW 2009/10 collection during Paris Fashion Week
fashionMeet the collaborators who helped create the late designer’s notorious spectacles
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

Day In a Page

War with Isis: Fears that the looming battle for Mosul will unleash 'a million refugees'

The battle for Mosul will unleash 'a million refugees'

Aid agencies prepare for vast exodus following planned Iraqi offensive against the Isis-held city, reports Patrick Cockburn
Yvette Cooper: We can't lose the election. There's too much on the line

Yvette Cooper: We can't lose the election. There's too much on the line

The shadow Home Secretary on fighting radical Islam, protecting children, and why anyone in Labour who's thinking beyond May must 'sort themselves out'
A bad week for the Greens: Leader Natalie Bennett's 'car crash' radio interview is followed by Brighton council's failure to set a budget due to infighting

It's not easy being Green

After a bad week in which its leader had a public meltdown and its only city council couldn't agree on a budget vote, what next for the alternative party? It's over to Caroline Lucas to find out
Gorillas nearly missed: BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter

Gorillas nearly missed

BBC producers didn't want to broadcast Sir David Attenborough's famed Rwandan encounter
Downton Abbey effect sees impoverished Italian nobles inspired to open their doors to paying guests for up to €650 a night

The Downton Abbey effect

Impoverished Italian nobles are opening their doors to paying guests, inspired by the TV drama
China's wild panda numbers have increased by 17% since 2003, new census reveals

China's wild panda numbers on the up

New census reveals 17% since 2003
Barbara Woodward: Britain's first female ambassador to China intends to forge strong links with the growing economic superpower

Our woman in Beijing builds a new relationship

Britain's first female ambassador to China intends to forge strong links with growing economic power
Courage is rare. True humility is even rarer. But the only British soldier to be awarded the Victoria Cross in Afghanistan has both

Courage is rare. True humility is even rarer

Beware of imitations, but the words of the soldier awarded the Victoria Cross were the real thing, says DJ Taylor
Alexander McQueen: The catwalk was a stage for the designer's astonishing and troubling vision

Alexander McQueen's astonishing vision

Ahead of a major retrospective, Alexander Fury talks to the collaborators who helped create the late designer's notorious spectacle
New BBC series savours half a century of food in Britain, from Vesta curries to nouvelle cuisine

Dinner through the decades

A new BBC series challenged Brandon Robshaw and his family to eat their way from the 1950s to the 1990s
Philippa Perry interview: The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course

Philippa Perry interview

The psychotherapist on McDonald's, fancy specs and meeting Grayson Perry on an evening course
Bill Granger recipes: Our chef recreates the exoticism of the Indonesian stir-fry

Bill Granger's Indonesian stir-fry recipes

Our chef was inspired by the south-east Asian cuisine he encountered as a teenager
Chelsea vs Tottenham: Harry Kane was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope

Harry Kane interview

The striker was at Wembley to see Spurs beat the Blues and win the Capital One Cup - now he's their great hope
The Last Word: For the good of the game: why on earth don’t we leave Fifa?

Michael Calvin's Last Word

For the good of the game: why on earth don’t we leave Fifa?
HIV pill: Scientists hail discovery of 'game-changer' that cuts the risk of infection among gay men by 86%

Scientists hail daily pill that protects against HIV infection

Breakthrough in battle against global scourge – but will the NHS pay for it?